IBRX ImmunityBio Inc

$IBRX I have to say that I have never been on a board where I have liked every comment. I have the creeps blocked. But the people here are acceptional. The best. We have a very impressive group here that matches our commitment. Very cool.

$IBRX This post utilizes screen shots on the GBM study that will be shared this Friday. I encourage all of you to open the link in my previous post to discern everything for yourselves. This appears bullish to me.

$IBRX Good morning fellow investors and those of us who trust in Dr. Patrick’s medical revolution, a large list of catalysts: The FDA has approved ANKTIVA in combination with BCG / Papillary NMIBC label expansion. Lymphopenia and Pancreatic cancer, both have - RMAT designations since February 2025. To date no treatment exists for Lymphopenia. “ImmunityBio Received FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors JUNE 2, 2025” Global expansion in new markets, 34 countries the EU (Portugal & Greece), UK, Japan, Saudi Arabia, United Arab Emirates Macau, India, South Africa, Albania and Turkey, etc. An international corporate office in Dublin Ireland (ImmunityBio Ireland Limited) supporting the European launch of ANKTIVA and distribution partnership in the EU with an 85-person sales force. Pending Saudi Arabia/MENA’s. announcement lung cancer results. “On July 29, 2026, the United Arab Emirates, Emirates Drug establishment granted marketing authorization to ImmunityBio for its cancer immunotherapy drug - ANKTIVA for advanced bladder and lung cancer indications.” On September 7, Albania signed memorandum of corporation to cancer treatment and access to ImmunityBio’s technologies. Former World Bank President Dr. Jim Yong Kim is the Vice Chairman to lead international expansion and global market access. Approval of Japanese BCG. Approval of NANT Leonardo artificial intelligence robotic mass production system of natural killer (NK) cells certification. Creating World Bank of NK cells and T cells are collected, engineered and then infused back in to the patient. Announcement of 1st line bladder cancer trial results (Oct 26). Start of sepsis trial with NANT Leonardo. Approval for Lymphopenia (Q4 2026). ANKTIVA will cure other cancers such as Glioblastoma (brain), Prostate, Pancreatic,Head & Neck, Colon, Liver, Ovarian, Lung, Indolent non-Hodgkin lymphoma, including Waldenström macroglobulinemia. A strong pipeline. Long Covid. Infection like HIV and Sepsis. Lynch syndrome (CANCER PREVENTION VACCINE). “A decade of work coming to fruition”. Next generation of CAR-T therapy for leukemias. “Orchestrating the complex machinery of our immune system is the B cell and the immense diversity of antibodies.” Announcement of 100% disease control for Glioblastoma, 19 out of 23 enrolled patients remain alive. Standard therapies typically yield a survival window of just 6 to 9 months. Approval of GBM accelerated (Q2 2027). Announcement of initial M-ceNK results. (9.1.2027). RMAT designation for M-ceNK. Accelerated approval of sepsis. Chemotherapy free immune based oncology. ANKTIVA IL-15 will improve aging and longevity. Other new events: “Honored to have been invited to give a one hour lecture to NIH and NCI about our 20 years of work on a cancer vaccine and our collaboration with NCI. Had a great talk and great feedback..apparently over 170 people attended the talk Friday. Will send a link once I get the recording. ALC matters!” 2) “The most precise cancer target ever discovered is not a drug company's molecule. It is the neoepitope... The mutation only your tumor carries, invisible to normal cells. Find it and present it. Let the immune system do what it was evolved to do. Our cancer moonshot coming to fruition.” A vertically integrated company. Dunkirk plant, in recent months, 24 tractor trailer loads of highly specialized manufacturing equipment have been delivered to the site, custom designed in Italy. With the new state-of-the-art equipment, approximately 400 vials per minute can be produced. ANKTIVA has a shelf life of over four years, does not require freezing—standard refrigeration is sufficient for storage—and, finally, does not require hospitalization. 240 million people are covered by insurance companies. We have to recover from last week’s naked short selling crime. They should pay dearly with a short squeeze for betting against a cancer cure. Buy and hold!

$IBRX For all our new interested parties - welcome! You've invested in a world-changing bio company. Understand ALL the news from the past 36 months has been positive for both investors, and perhaps most immpotantly, for patients. Anktiva is real. It works. It bested Keytuda over 15 years ago and continues to provide lifechanging efficacy. JNJ has something similar but with severe side effects. Keytruda continues to be the oncologist kickback engine - YES, they get paid to prescribe it with reduced fees/$$$ for their practice/hospital/personally from Merck. Unethical as shit but real life. JNJ does the same. Pay for play isn't just sports! Anticipate orchestrated desperation moves this week to thwart IBRX's recent news. We'll get this lawsuit announcement pinned on our ST page,Fraudstein will post every day on X, SeekingAlpha will be paid to do another hit piece, and no doubt Merck/JNJ will spew lies on conference calls dismissing IBRX as 'snake oil'. Ignore and keep the faith!

$IBRX I have little to no doubt that if Pat were to ever sell IBRX to big pharma, Fraudstein and all the other cockroaches would hail IL-15 as the greatest cancer fighter ever. Media coverage would be everywhere and FDA expansion would get expedited. You don’t hate big pharma, The FDA and greedy interests enough.

$IBRX One of Richard Adcock’s greatest skills was demonstrated following Anktiva’s FDA approval in 2024, which launched and began reaching parients within 30 days following the FDA decision. Frankly, that is unheard of among biotechs receiving their first drug approvals! Anktiva for NMIBC (Papillary-Only), Adcock has the advantage of the NCCN having already endorsed Anktiva for the papillary only indication, ImmunityBio will hit the ground running gaining immediate acceptance by all major medical reimbursement companies. This is where Adcock’s team has proven to excel and will result in an immediate and substantial impact in Anktiva sales revenue.

$IBRX instead of 22 cysectomies a day, if all papillary patients take Anktiva , that number would be less than 1 a day.

$IBRX I say we all call the law firm of “Do we , cheetum, and how”, or this scumbag firm of “Bronstein, Gerwitz, & Grossman” tomorrow- and all tell them they should tell their clients to cover their short position, and then tell them to fuck off! Any thoughts?

$IBRX ...IBRX ticker seen coming across the CNBC scroll bar several times this morning!! Just FYI...

$IBRX Sufficient BCG Supply for Expanded Addressable Population: ImmunityBio has established relationships with global BCG suppliers (such as Serum Institute of India) to ensure commercial doses remain fully available, accommodating the expanded patient base following the recent FDA approval for papillary-only NMIBC. Capitalizing on the Larger Papillary Market: Papillary disease accounts for ~85% of NMIBC diagnoses. Having guaranteed BCG access removes a key bottleneck that historically constrained intravesical therapy adoption during nationwide shortages.

$IBRX I couldn't help myself. I just bought another 1k shares after telling myself that I was done buying.. This price will not stay this low for very long. My last purchase was in June '26. I now have 18k shares.

$IBRX This same firm opened investigations on SLS.🤣😂🤣 Its just a scare tactic not even an open lawsuit. Somebody should look up how many of these investigations they have open on all possible bio techs 😂🤣😂🤣 This firm is a joke. Real investors can smell th BS.

$IBRX Sandler Chat ~ Part 2 ~ Long-Term Phase 3 Efficacy Data Cystectomy Avoidance: Data from the QUILT-3.032 trial showed an 84% cystectomy-free survival rate at 36 months among responding patients. Durable Complete Responses (CR): Responders achieved a median duration of complete response of 26.6 months, with ongoing responses extending beyond 53 months. Over half of responding patients maintained complete responses beyond 45 months. High Overall Survival: High disease-specific survival reached 98.2% at 3 years, with only 4% of responders progressing to muscle-invasive disease. Commercial Rollout & Execution BCG Supply & Distribution: Discussion emphasized ongoing execution with key hospital networks and urology clinics, leveraging the expanded label to accelerate commercial adoption across both academic centers and community urology practices.

$IBRX So this Friday, we will have two follow ups. FIRST NSCLC and second GMB. Open the links and see for yourselves, I look forward to hearing from our resident scientists. Screen shots from NSCLC, Looks good to me!

$IBRX Dr PSS and team actively negotiating / discussing broad Bioshield approvals w UAE. This includes lymphopenia.

$IBRX Good morning from sunny Crisp Connecticut! Could be quite on the news front until earnings in November… you never know. Either way should be an interesting week for both IBRX and the market. Stay positive and Have a great day!

$IBRX quite the trend i've noticed. ibrx announces good news. Adam Fckstain comments. The same 2 SA authors release articles downplaying the news. A week later nobody cares or remembers the drama and progress continues.

$IBRX Put it into context. IMHO, this is NOT some bad news or some large investor selling out. This is an INTENTIONAL smack down in order to force retail into a panic selloff. I’m open to other interpretations, but this is the only logical explanation that I see as all news has been terrific to date. GLTA longs… ignore the BS 😎👍

$IBRX Ask yourself the data was great, early FDA approval, potentially great earnings coming out you think these Cocoroaches will make it easy and take this to the moon? I don’t think so. The reality is these disgusting filth people will try to shake everyone off and grab your shares for cheaps. Don’t fall for games lock your shares and keep adding. Fill up your bags to maximum!!!

$IBRX Never in my decades following Biotech have I seen a Biotech selloff 20% after an early FDA Approval that increases the treatable Patient population by 4 times minimum. In fact, the investor expectation was a likelihood of the FDA playing more games to delay approval once again. The pressure on the FDA and Administration is still directed to All Cancer Lymphopenia and a growing waitlist. Friday’s stratified NSCLC results will support ‘All Cancer’ Approval. There are not many cancer drugs where response is 100% measurable, by rise in ALC back to normal levels. Treating ‘Failed CPI Patients’ still stacks the deck against ImmunityBio, but results speak for themselves.